Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 94
Filter
1.
mSphere ; 7(1): e0098421, 2022 02 23.
Article in English | MEDLINE | ID: mdl-35044807

ABSTRACT

Streptococcus pneumoniae (the pneumococcus) is a leading cause of pneumonia in children under 5 years of age. Coinfection by pneumococci and respiratory viruses enhances disease severity. Little is known about pneumococcal coinfections with respiratory syncytial virus (RSV). Here, we developed a novel infant mouse model of coinfection using pneumonia virus of mice (PVM), a murine analogue of RSV, to examine the dynamics of coinfection in the upper respiratory tract, an anatomical niche that is essential for host-to-host transmission and progression to disease. Coinfection increased damage to the nasal tissue and increased production of the chemokine CCL3. Nasopharyngeal pneumococcal density and shedding in nasal secretions were increased by coinfection. In contrast, coinfection reduced PVM loads in the nasopharynx, an effect that was independent of pneumococcal strain and the order of infection. We showed that this "antagonistic" effect was absent using either ethanol-killed pneumococci or a pneumococcal mutant deficient in capsule production and incapable of nasopharyngeal carriage. Colonization with a pneumococcal strain naturally unable to produce capsule also reduced viral loads. The pneumococcus-mediated reduction in PVM loads was caused by accelerated viral clearance from the nasopharynx. Although these synergistic and antagonistic effects occurred with both wild-type pneumococcal strains used in this study, the magnitude of the effects was strain dependent. Lastly, we showed that pneumococci can also antagonize influenza virus. Taken together, our study has uncovered multiple novel facets of bacterial-viral coinfection. Our findings have important public health implications, including for bacterial and viral vaccination strategies in young children. IMPORTANCE Respiratory bacterial-viral coinfections (such as pneumococci and influenza virus) are often synergistic, resulting in enhanced disease severity. Although colonization of the nasopharynx is the precursor to disease and transmission, little is known about bacterial-viral interactions that occur within this niche. In this study, we developed a novel mouse model to examine pneumococcal-viral interactions in the nasopharynx with pneumonia virus of mice (PVM) and influenza. We found that PVM infection benefits pneumococci by increasing their numbers in the nasopharynx and shedding of these bacteria in respiratory secretions. In contrast, we discovered that pneumococci decrease PVM numbers by accelerating viral clearance. We also report a similar effect of pneumococci on influenza. By showing that coinfections lead to both synergistic and antagonistic outcomes, our findings challenge the existing dogma in the field. Our work has important applications and implications for bacterial and viral vaccines that target these microbes.


Subject(s)
Antibiosis , Coinfection/microbiology , Coinfection/virology , Pneumococcal Infections/virology , Pneumovirus Infections/virology , Respiratory System/virology , Age Factors , Animals , Coinfection/immunology , Cytokines/analysis , Cytokines/immunology , Disease Models, Animal , Influenza A virus/genetics , Influenza A virus/immunology , Mice , Mice, Inbred C57BL , Murine pneumonia virus/genetics , Murine pneumonia virus/immunology , Nasopharynx/virology , Orthomyxoviridae Infections/immunology , Orthomyxoviridae Infections/virology , Pneumovirus Infections/immunology , Respiratory System/immunology , Streptococcus pneumoniae/genetics , Streptococcus pneumoniae/immunology , Viral Load
2.
Cancer Sci ; 112(11): 4526-4542, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34533860

ABSTRACT

Melanoma is a fatal skin malignant tumor with a poor prognosis. We found that long noncoding RNA BASP1-AS1 is essential for the development and prognosis of melanoma. The methylation, RNA sequencing, copy number variation, mutation data, and sample follow-up information of melanoma from The Cancer Genome Atlas (TCGA) were analyzed using weighted gene co-expression network analysis and 366 samples common to the three omics were selected for multigroup clustering analysis. A four-gene prognostic model (BASP1-AS1, LOC100506098, ARHGAP27P1, and LINC01532) was constructed in the TCGA cohort and validated using the GSE65904 series. The expression of BASP1-AS1 was upregulated in melanoma tissues and various melanoma cell lines. Functionally, the ectopic expression of BASP1-AS1 promoted cell proliferation, migration, and invasion in both A375 and SK-MEL-2 cells. Mechanically, BASP1-AS1 interacted with YBX1 and recruited it to the promoter of NOTCH3, initiating its transcription process. The activation of the Notch signaling then resulted in the transcription of multiple oncogenes, including c-MYC, PCNA, and CDK4, which contributed to melanoma progression. Thus, BASP1-AS1 could act as a potential biomarker for cutaneous malignant melanoma.


Subject(s)
Melanoma/metabolism , Membrane Proteins/metabolism , Nerve Tissue Proteins/metabolism , RNA, Long Noncoding/metabolism , Receptor, Notch3/metabolism , Repressor Proteins/metabolism , Skin Neoplasms/metabolism , Y-Box-Binding Protein 1/metabolism , Animals , Cell Line, Tumor , Cell Movement , Cell Proliferation , GTPase-Activating Proteins/metabolism , Gene Silencing , Humans , Male , Melanoma/mortality , Melanoma/pathology , Membrane Proteins/genetics , Mice , Mice, Inbred BALB C , Murine pneumonia virus , Neoplasm Invasiveness , Neoplasm Proteins/metabolism , Neoplasm Transplantation , Neoplastic Stem Cells , Nerve Tissue Proteins/genetics , Prognosis , Proto-Oncogene Proteins c-bcl-2/metabolism , Random Allocation , Repressor Proteins/genetics , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Transcription, Genetic , Up-Regulation , Melanoma, Cutaneous Malignant
3.
mSphere ; 6(3): e0047921, 2021 06 30.
Article in English | MEDLINE | ID: mdl-34160242

ABSTRACT

Coinfection by heterologous viruses in the respiratory tract is common and can alter disease severity compared to infection by individual virus strains. We previously found that inoculation of mice with rhinovirus (RV) 2 days before inoculation with a lethal dose of influenza A virus [A/Puerto Rico/8/34 (H1N1) (PR8)] provides complete protection against mortality. Here, we extended that finding to a second lethal respiratory virus, pneumonia virus of mice (PVM), and analyzed potential mechanisms of RV-induced protection. RV completely prevented mortality and weight loss associated with PVM infection. Major changes in host gene expression upon PVM infection were delayed compared to PR8. RV induced earlier recruitment of inflammatory cells, which were reduced at later times in RV-inoculated mice. Findings common to both virus pairs included the upregulated expression of mucin-associated genes and dampening of inflammation-related genes in mice that were inoculated with RV before lethal virus infection. However, type I interferon (IFN) signaling was required for RV-mediated protection against PR8 but not PVM. IFN signaling had minor effects on PR8 replication and contributed to controlling neutrophilic inflammation and hemorrhagic lung pathology in RV/PR8-infected mice. These findings, combined with differences in virus replication levels and disease severity, suggest that the suppression of inflammation in RV/PVM-infected mice may be due to early, IFN-independent suppression of viral replication, while that in RV/PR8-infected mice may be due to IFN-dependent modulation of immune responses. Thus, a mild upper respiratory viral infection can reduce the severity of a subsequent severe viral infection in the lungs through virus-dependent mechanisms. IMPORTANCE Respiratory viruses from diverse families cocirculate in human populations and are frequently detected within the same host. Although clinical studies suggest that infection by multiple different respiratory viruses may alter disease severity, animal models in which we can control the doses, timing, and strains of coinfecting viruses are critical to understanding how coinfection affects disease severity. Here, we compared gene expression and immune cell recruitment between two pairs of viruses (RV/PR8 and RV/PVM) inoculated sequentially in mice, both of which result in reduced severity compared to lethal infection by PR8 or PVM alone. Reduced disease severity was associated with suppression of inflammatory responses in the lungs. However, differences in disease kinetics and host and viral gene expression suggest that protection by coinfection with RV may be due to distinct molecular mechanisms. Indeed, we found that antiviral cytokine signaling was required for RV-mediated protection against lethal infection by PR8 but not PVM.


Subject(s)
Coinfection/immunology , Host-Pathogen Interactions , Interferon Type I/immunology , Picornaviridae Infections/immunology , Rhinovirus/immunology , Rhinovirus/pathogenicity , Animals , Coinfection/virology , Female , Host-Pathogen Interactions/genetics , Host-Pathogen Interactions/immunology , Influenza A virus/immunology , Influenza A virus/pathogenicity , Lung/immunology , Lung/pathology , Lung/virology , Mice , Mice, Inbred BALB C , Murine pneumonia virus/immunology , Murine pneumonia virus/pathogenicity , Orthomyxoviridae Infections/immunology , Orthomyxoviridae Infections/prevention & control , Pneumovirus Infections/immunology , Pneumovirus Infections/prevention & control , Severity of Illness Index , Transcriptome , Virus Replication
4.
Viruses ; 13(5)2021 04 22.
Article in English | MEDLINE | ID: mdl-33922096

ABSTRACT

Respiratory virus infections can have long-term effects on lung function that persist even after the acute responses have resolved. Numerous studies have linked severe early childhood infection with respiratory syncytial virus (RSV) to the development of wheezing and asthma, although the underlying mechanisms connecting these observations remain unclear. Here, we examine airway hyperresponsiveness (AHR) that develops in wild-type mice after recovery from symptomatic but sublethal infection with the natural rodent pathogen, pneumonia virus of mice (PVM). We found that BALB/c mice respond to a limited inoculum of PVM with significant but reversible weight loss accompanied by virus replication, acute inflammation, and neutrophil recruitment to the airways. At day 21 post-inoculation, virus was no longer detected in the airways and the acute inflammatory response had largely resolved. However, and in contrast to most earlier studies using the PVM infection model, all mice survived the initial infection and all went on to develop serum anti-PVM IgG antibodies. Furthermore, using both invasive plethysmography and precision-cut lung slices, we found that these mice exhibited significant airway hyperresponsiveness at day 21 post-inoculation that persisted through day 45. Taken together, our findings extend an important and versatile respiratory virus infection model that can now be used to explore the role of virions and virion clearance as well as virus-induced inflammatory mediators and their signaling pathways in the development and persistence of post-viral AHR and lung dysfunction.


Subject(s)
Murine pneumonia virus/immunology , Pneumovirus Infections/complications , Pneumovirus Infections/veterinary , Respiratory Hypersensitivity/etiology , Animals , Antibodies, Viral/immunology , Humans , Lung/immunology , Lung/virology , Mice , Mice, Inbred BALB C , Murine pneumonia virus/physiology , Pneumovirus Infections/immunology , Pneumovirus Infections/virology , Respiratory Hypersensitivity/immunology , Respiratory Hypersensitivity/virology , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Virus Infections/virology , Respiratory Syncytial Virus, Human/immunology , Respiratory Syncytial Virus, Human/physiology
5.
Antiviral Res ; 171: 104594, 2019 11.
Article in English | MEDLINE | ID: mdl-31470041

ABSTRACT

Respiratory syncytial virus (RSV) is responsible for a large proportion of acute lower respiratory tract infections, specifically in children. Pneumonia virus of mice (PVM) causes similar lung pathology and clinical disease in rodents, and is therefore an appropriate model of RSV infection. Previously, we demonstrated that a single intranasal dose of P-I-P, a novel immunomodulator composed of the toll-like receptor 3 agonist poly(I:C), an innate defense regulator peptide and a polyphosphazene, confers protection in Balb/c mice for up to 3 days from lethal PVM-15 infection. In the present study a dual intranasal treatment with P-I-P was shown to extend the duration of the protection conferred by P-I-P from PVM-15 challenge. Balb/c mice treated twice with P-I-P showed higher survival rates and milder clinical signs when compared to animals that received a single P-I-P dose. While the mice treated with two consecutive doses of P-I-P experienced some weight loss, they all recovered. The dual P-I-P treatment mediated infiltration of several innate immune cells into the BALF and lung, including alveolar macrophages, neutrophils, and γδ T cells. Partial depletion of alveolar macrophages decreased survival rates and exacerbated clinical signs of mice subjected to the P-I-P dual treatment regime followed by PVM-15 challenge. This suggests that the alveolar macrophage is at least partially responsible for the protection elicited by this novel prophylactic treatment strategy.


Subject(s)
Immunity, Innate , Immunologic Factors/pharmacology , Macrophages/drug effects , Macrophages/immunology , Murine pneumonia virus/drug effects , Murine pneumonia virus/immunology , Pneumovirus Infections/immunology , Pneumovirus Infections/virology , Animals , Cell Line , Cytokines/biosynthesis , Cytokines/blood , Female , Host-Pathogen Interactions , Immunologic Factors/administration & dosage , Macrophages/metabolism , Macrophages/virology , Mice , Pneumovirus Infections/drug therapy , Pneumovirus Infections/mortality
6.
J Immunol ; 202(3): 871-882, 2019 02 01.
Article in English | MEDLINE | ID: mdl-30578308

ABSTRACT

Severe respiratory virus infections feature robust local host responses that contribute to disease severity. Immunomodulatory strategies that limit virus-induced inflammation may be of critical importance, notably in the absence of antiviral vaccines. In this study, we examined the role of the pleiotropic cytokine IL-6 in acute infection with pneumonia virus of mice (PVM), a natural rodent pathogen that is related to respiratory syncytial virus and that generates local inflammation as a feature of severe infection. In contrast to Influenza A, PVM is substantially less lethal in IL-6 -/- mice than it is in wild-type, a finding associated with diminished neutrophil recruitment and reduced fluid accumulation in lung tissue. Ly6Chi proinflammatory monocytes are recruited in response to PVM via a CCR2-dependent mechanism, but they are not a major source of IL-6 nor do they contribute to lethal sequelae of infection. By contrast, alveolar macrophages are readily infected with PVM in vivo; ablation of alveolar macrophages results in prolonged survival in association with a reduction in virus-induced IL-6. Finally, as shown previously, administration of immunobiotic Lactobacillus plantarum to the respiratory tracts of PVM-infected mice promoted survival in association with diminished levels of IL-6. We demonstrated in this study that IL-6 suppression is a critical feature of the protective mechanism; PVM-infected IL-6 -/- mice responded to low doses of L. plantarum, and administration of IL-6 overcame L. plantarum-mediated protection in PVM-infected wild-type mice. Taken together, these results connect the actions of IL-6 to PVM pathogenesis and suggest cytokine blockade as a potential therapeutic modality in severe infection.


Subject(s)
Interleukin-6/immunology , Murine pneumonia virus/immunology , Pneumovirus Infections/immunology , Animals , Inflammation , Interleukin-6/pharmacology , Lactobacillus plantarum/immunology , Lung/immunology , Macrophages, Alveolar/immunology , Macrophages, Alveolar/virology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Probiotics/administration & dosage , Recombinant Proteins/immunology , Recombinant Proteins/pharmacology , Respiratory System/immunology , Respiratory System/virology
7.
J Virol ; 92(17)2018 09 01.
Article in English | MEDLINE | ID: mdl-29925656

ABSTRACT

Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. Like RSV, Murine pneumonia virus (MPV) is a member of the genus Orthopneumovirus, family Pneumoviridae Humans are not normally exposed to MPV, and MPV is not cross-protective with RSV. We evaluated MPV as an RSV vaccine vector expressing the RSV fusion (F) glycoprotein. The RSV F open reading frame (ORF) was codon optimized, and the encoded RSV F protein was made identical to an early passage of RSV strain A2. The RSV F ORF was placed under the control of MPV transcription signals and inserted at the first (rMPV-F1), third (rMPV-F3), or fourth (rMPV-F4) gene position of a version of the MPV genome that contained a codon-pair-optimized polymerase (L) gene. The recovered viruses replicated in vitro as efficiently as the empty vector, with stable expression of RSV F protein. Replication and immunogenicity of rMPV-F1 and rMPV-F3 were evaluated in rhesus macaques following intranasal and intratracheal administration. Both viruses replicated at low levels in the upper and lower respiratory tracts, maintained stable RSV F expression, and induced RSV-neutralizing serum antibodies at high levels similar to those induced by wild-type RSV replicating to a 5- to 25-fold-higher titer. In conclusion, this study demonstrated that rMPV provides a highly attenuated yet immunogenic vector for the expression of RSV F protein, with potential application in RSV-naive and RSV-experienced populations.IMPORTANCE Human respiratory syncytial virus (RSV) is an important human pathogen that lacks a licensed vaccine or antiviral drug suitable for routine use. We describe here the evaluation of recombinant murine pneumonia virus (rMPV) as a live-attenuated vector that expresses the RSV F protein, the major RSV neutralization antigen, as an experimental RSV vaccine. The rMPV-RSV-F vectors expressing RSV F from the first, third, or fourth gene position were genetically stable and were not restricted for replication in vitro In contrast, the vectors exhibited highly attenuated replication in the respiratory tract of rhesus macaques, maintained stable RSV F expression, and induced RSV-neutralizing serum antibodies at high titers similar to those conferred by wild-type RSV. Given the lack of preexisting immunity to MPV in humans and the lack of cross-neutralization and cross-protection between MPV and RSV, an rMPV-vectored RSV vaccine should be immunogenic in both RSV-naive children and RSV-experienced adults.


Subject(s)
Murine pneumonia virus/genetics , Respiratory Syncytial Virus Vaccines/immunology , Respiratory Syncytial Virus, Human/genetics , Viral Fusion Proteins/immunology , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Antibodies, Viral/immunology , Chlorocebus aethiops , Genetic Vectors , Humans , Macaca mulatta , Mice , Murine pneumonia virus/immunology , Murine pneumonia virus/metabolism , Respiratory Syncytial Virus Vaccines/administration & dosage , Respiratory Syncytial Virus Vaccines/genetics , Respiratory Syncytial Virus, Human/immunology , Vaccines, Attenuated/genetics , Vaccines, Attenuated/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology , Vero Cells , Viral Fusion Proteins/genetics , Virus Replication
8.
Sci Transl Med ; 10(440)2018 05 09.
Article in English | MEDLINE | ID: mdl-29743346

ABSTRACT

Prostaglandin D2 (PGD2) signals through PGD2 receptor 2 (DP2, also known as CRTH2) on type 2 effector cells to promote asthma pathogenesis; however, little is known about its role during respiratory syncytial virus (RSV) bronchiolitis, a major risk factor for asthma development. We show that RSV infection up-regulated hematopoietic prostaglandin D synthase expression and increased PGD2 release by cultured human primary airway epithelial cells (AECs). Moreover, PGD2 production was elevated in nasopharyngeal samples from young infants hospitalized with RSV bronchiolitis compared to healthy controls. In a neonatal mouse model of severe viral bronchiolitis, DP2 antagonism decreased viral load, immunopathology, and morbidity and ablated the predisposition for subsequent asthma onset in later life. This protective response was abolished upon dual DP1/DP2 antagonism and replicated with a specific DP1 agonist. Rather than mediating an effect via type 2 inflammation, the beneficial effects of DP2 blockade or DP1 agonism were associated with increased interferon-λ (IFN-λ) [interleukin-28A/B (IL-28A/B)] expression and were lost upon IL-28A neutralization. In RSV-infected AEC cultures, DP1 activation up-regulated IFN-λ production, which, in turn, increased IFN-stimulated gene expression, accelerating viral clearance. Our findings suggest that DP2 antagonists or DP1 agonists may be useful antivirals for the treatment of viral bronchiolitis and possibly as primary preventatives for asthma.


Subject(s)
Bronchiolitis, Viral/metabolism , Bronchiolitis, Viral/pathology , Interferon-gamma/biosynthesis , Prostaglandin D2/metabolism , Receptors, Immunologic/metabolism , Receptors, Prostaglandin/metabolism , Allergens , Animals , Animals, Newborn , Antiviral Agents/metabolism , Epithelial Cells/pathology , Epithelial Cells/virology , Humans , Immunity , Infant , Inflammation/pathology , Inflammation/virology , Intramolecular Oxidoreductases/metabolism , Lung/pathology , Lung/virology , Mice, Inbred BALB C , Murine pneumonia virus , Receptors, Immunologic/antagonists & inhibitors , Receptors, Prostaglandin/antagonists & inhibitors , Respiratory Syncytial Virus Infections/virology , Respiratory Syncytial Viruses/physiology , Up-Regulation
9.
J Immunol ; 200(2): 632-642, 2018 01 15.
Article in English | MEDLINE | ID: mdl-29212906

ABSTRACT

A link between inflammatory disease and bone loss is now recognized. However, limited data exist on the impact of virus infection on bone loss and regeneration. Bone loss results from an imbalance in remodeling, the physiological process whereby the skeleton undergoes continual cycles of formation and resorption. The specific molecular and cellular mechanisms linking virus-induced inflammation to bone loss remain unclear. In the current study, we provide evidence that infection of mice with either lymphocytic choriomeningitis virus (LCMV) or pneumonia virus of mice (PVM) resulted in rapid and substantial loss of osteoblasts from the bone surface. Osteoblast ablation was associated with elevated levels of circulating inflammatory cytokines, including TNF-α, IFN-γ, IL-6, and CCL2. Both LCMV and PVM infections resulted in reduced osteoblast-specific gene expression in bone, loss of osteoblasts, and reduced serum markers of bone formation, including osteocalcin and procollagen type 1 N propeptide. Infection of Rag-1-deficient mice (which lack adaptive immune cells) or specific depletion of CD8+ T lymphocytes limited osteoblast loss associated with LCMV infection. By contrast, CD8+ T cell depletion had no apparent impact on osteoblast ablation in association with PVM infection. In summary, our data demonstrate dramatic loss of osteoblasts in response to virus infection and associated systemic inflammation. Further, the inflammatory mechanisms mediating viral infection-induced bone loss depend on the specific inflammatory condition.


Subject(s)
Lymphocytic Choriomeningitis/immunology , Lymphocytic Choriomeningitis/virology , Lymphocytic choriomeningitis virus/immunology , Murine pneumonia virus/immunology , Osteoblasts/virology , Pneumovirus Infections/immunology , Pneumovirus Infections/virology , Animals , Biomarkers , Bone Marrow/pathology , Bone and Bones/metabolism , Bone and Bones/pathology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Cytokines/metabolism , Homeodomain Proteins/genetics , Lymphocyte Depletion , Mice , Mice, Knockout , Osteoblasts/immunology , Osteogenesis
10.
J Allergy Clin Immunol ; 141(5): 1607-1619.e9, 2018 05.
Article in English | MEDLINE | ID: mdl-28947081

ABSTRACT

BACKGROUND: Rhinovirus infection triggers acute asthma exacerbations. IL-33 is an instructive cytokine of type 2 inflammation whose expression is associated with viral load during experimental rhinovirus infection of asthmatic patients. OBJECTIVE: We sought to determine whether anti-IL-33 therapy is effective during disease progression, established disease, or viral exacerbation using a preclinical model of chronic asthma and in vitro human primary airway epithelial cells (AECs). METHODS: Mice were exposed to pneumonia virus of mice and cockroach extract in early and later life and then challenged with rhinovirus to model disease onset, progression, and chronicity. Interventions included anti-IL-33 or dexamethasone at various stages of disease. AECs were obtained from asthmatic patients and healthy subjects and treated with anti-IL-33 after rhinovirus infection. RESULTS: Anti-IL-33 decreased type 2 inflammation in all phases of disease; however, the ability to prevent airway smooth muscle growth was lost after the progression phase. After the chronic phase, IL-33 levels were persistently high, and rhinovirus challenge exacerbated the type 2 inflammatory response. Treatment with anti-IL-33 or dexamethasone diminished exacerbation severity, and anti-IL-33, but not dexamethasone, promoted antiviral interferon expression and decreased viral load. Rhinovirus replication was higher and IFN-λ levels were lower in AECs from asthmatic patients compared with those from healthy subjects. Anti-IL-33 decreased rhinovirus replication and increased IFN-λ levels at the gene and protein levels. CONCLUSION: Anti-IL-33 or dexamethasone suppressed the magnitude of type 2 inflammation during a rhinovirus-induced acute exacerbation; however, only anti-IL-33 boosted antiviral immunity and decreased viral replication. The latter phenotype was replicated in rhinovirus-infected human AECs, suggesting that anti-IL-33 therapy has the additional benefit of enhancing host defense.


Subject(s)
Antiviral Agents/pharmacology , Asthma/drug therapy , Asthma/immunology , Inflammation/immunology , Interleukin-33/immunology , Murine pneumonia virus/drug effects , Murine pneumonia virus/immunology , Animals , Antiviral Agents/immunology , Asthma/virology , Disease Susceptibility/immunology , Disease Susceptibility/virology , Epithelial Cells/drug effects , Epithelial Cells/immunology , Epithelial Cells/virology , Inflammation/drug therapy , Inflammation/virology , Mice , Mice, Inbred BALB C , Pneumovirus Infections/drug therapy , Pneumovirus Infections/immunology , Pneumovirus Infections/virology , Viral Load/drug effects , Viral Load/immunology
11.
Virol J ; 14(1): 215, 2017 11 06.
Article in English | MEDLINE | ID: mdl-29110727

ABSTRACT

BACKGROUND: Interferon (IFN) inhibits viruses by inducing several hundred cellular genes, aptly named 'interferon (IFN)-stimulated genes' (ISGs). The only two RNA viruses of the Pneumovirus genus of the Paramyxoviridae family, namely Respiratory Syncytial Virus (RSV) and Pneumonia Virus of Mice (PVM), each encode two nonstructural (NS) proteins that share no sequence similarity but yet suppress IFN. Since suppression of IFN underlies the ability of these viruses to replicate in the host cells, the mechanism of such suppression has become an important area of research. This Short Report is an important extension of our previous efforts in defining this mechanism. RESULTS: We show that, like their PVM counterparts, the RSV NS proteins also target multiple members of the ISG family. While significantly extending the substrate repertoire of the RSV NS proteins, these results, unexpectedly, also reveal that the target preferences of the NS proteins of the two viruses are entirely different. This is surprising since the two Pneumoviruses are phylogenetically close with similar genome organization and gene function, and the NS proteins of both also serve as suppressors of host IFN response. CONCLUSION: The finding that the NS proteins of the two highly similar viruses suppress entirely different members of the ISG family raises intriguing questions of pneumoviral NS evolution and mechanism of action.


Subject(s)
Murine pneumonia virus/physiology , Respiratory Syncytial Virus, Human/physiology , Viral Nonstructural Proteins/metabolism , Animals , Antiviral Agents/antagonists & inhibitors , Genetic Variation , HEK293 Cells , Host-Pathogen Interactions/genetics , Humans , Interferons/antagonists & inhibitors , Mice , Substrate Specificity , Viral Nonstructural Proteins/genetics
12.
Sci Rep ; 7(1): 3472, 2017 06 14.
Article in English | MEDLINE | ID: mdl-28615708

ABSTRACT

Pneumonia virus of mice (PVM) infection has been widely used as a rodent model to study the closely related human respiratory syncytial virus (hRSV). While T cells are indispensable for viral clearance, they also contribute to immunopathology. To gain more insight into mechanistic details, novel tools are needed that allow to study virus-specific T cells in C57BL/6 mice as the majority of transgenic mice are only available on this background. While PVM-specific CD8 T cell epitopes were recently described, so far no PVM-specific CD4 T cell epitopes have been identified within the C57BL/6 strain. Therefore, we set out to map H2-IAb-restricted epitopes along the PVM proteome. By means of in silico prediction and subsequent functional validation, we were able to identify a MHCII-restricted CD4 T cell epitope, corresponding to amino acids 37-47 in the PVM matrix protein (M37-47). Using this newly identified MHCII-restricted M37-47 epitope and a previously described MHCI-restricted N339-347 epitope, we generated peptide-loaded MHCII and MHCI tetramers and characterized the dynamics of virus-specific CD4 and CD8 T cell responses in vivo. The findings of this study can provide a basis for detailed investigation of T cell-mediated immune responses to PVM in a variety of genetically modified C57BL/6 mice.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Epitope Mapping , Epitopes, T-Lymphocyte/immunology , Immunity, Cellular , Murine pneumonia virus/immunology , Pneumonia, Viral/immunology , Amino Acid Sequence , Animals , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Cells, Cultured , Epitope Mapping/methods , Epitopes, T-Lymphocyte/chemistry , Female , Histocompatibility Antigens Class II/immunology , Kinetics , Mice , Mice, Inbred C57BL , Pneumonia, Viral/virology
13.
Sci Rep ; 7(1): 2353, 2017 05 24.
Article in English | MEDLINE | ID: mdl-28539639

ABSTRACT

Respiratory syncytial virus (RSV)-bronchiolitis is a major cause of infant morbidity and mortality and a risk factor for subsequent asthma. We showed previously that toll-like receptor (TLR)7 in plasmacytoid dendritic cells (pDCs) is critical for protection against bronchiolitis and asthma in mice infected with pneumonia virus of mice (PVM), the mouse homolog of RSV. This lack of redundancy was unexpected as interferon-ß promotor stimulator-1 (IPS-1) signalling, downstream of RIG-I-like receptor (RLR) and not TLR7 activation, contributes to host defence in hRSV-inoculated adult mice. To further clarify the role of IPS-1 signalling, we inoculated IPS-1-/- and WT mice with PVM in early-life, and again in later-life, to model the association between bronchiolitis and asthma. IPS-1 deficiency predisposed to severe PVM bronchiolitis, characterised by neutrophilic inflammation and necroptotic airway epithelial cell death, high mobility group box 1 (HMGB1) and IL-33 release, and downstream type-2 inflammation. Secondary infection induced an eosinophilic asthma-like pathophysiology in IPS-1-/- but not WT mice. Mechanistically, we identified that IPS-1 is necessary for pDC recruitment, IFN-α production and viral control. Our findings suggest that TLR7 and RLR signalling work collaboratively to optimally control the host response to pneumovirus infection thereby protecting against viral bronchiolitis and subsequent asthma.


Subject(s)
Adaptor Proteins, Signal Transducing/deficiency , Asthma/metabolism , Bronchiolitis/metabolism , Murine pneumonia virus/physiology , Pneumovirus Infections/virology , Adaptor Proteins, Signal Transducing/genetics , Animals , Asthma/genetics , Bronchiolitis/genetics , DEAD Box Protein 58/metabolism , Dendritic Cells/metabolism , Host-Pathogen Interactions , Interferon-alpha/metabolism , Membrane Glycoproteins/metabolism , Mice, Inbred C57BL , Mice, Knockout , Pneumovirus Infections/genetics , Pneumovirus Infections/metabolism , Signal Transduction , Toll-Like Receptor 7/metabolism
14.
Elife ; 62017 01 18.
Article in English | MEDLINE | ID: mdl-28099113

ABSTRACT

Asthma is a chronic inflammatory disease. Although many patients with asthma develop type-2 dominated eosinophilic inflammation, a number of individuals develop paucigranulocytic asthma, which occurs in the absence of eosinophilia or neutrophilia. The aetiology of paucigranulocytic asthma is unknown. However, both respiratory syncytial virus (RSV) infection and mutations in the receptor for advanced glycation endproducts (RAGE) are risk factors for asthma development. Here, we show that RAGE deficiency impairs anti-viral immunity during an early-life infection with pneumonia virus of mice (PVM; a murine analogue of RSV). The elevated viral load was associated with the release of high mobility group box-1 (HMGB1) which triggered airway smooth muscle remodelling in early-life. Re-infection with PVM in later-life induced many of the cardinal features of asthma in the absence of eosinophilic or neutrophilic inflammation. Anti-HMGB1 mitigated both early-life viral disease and asthma-like features, highlighting HMGB1 as a possible novel therapeutic target.


Subject(s)
Agranulocytosis/complications , Agranulocytosis/genetics , Asthma/genetics , Asthma/pathology , Genetic Predisposition to Disease , HMGB1 Protein/metabolism , Receptor for Advanced Glycation End Products/deficiency , Animals , Mice , Murine pneumonia virus/immunology , Viral Load
15.
PLoS One ; 11(12): e0168779, 2016.
Article in English | MEDLINE | ID: mdl-28005954

ABSTRACT

The human pneumovirus respiratory syncytial virus (RSV) is the most common pathogen causing lower respiratory tract disease in young children worldwide. A hallmark of severe human RSV infection is the strong neutrophil recruitment to the airways and lungs. Massive neutrophil activation has been proven detrimental in numerous diseases, yet in RSV the contribution of neutrophils to disease severity, and thereby, the relevance of targeting them, is largely unknown. To determine the relevance of potential neutrophil targeting therapies, we implemented antibody-mediated neutrophil depletion in a mouse pneumonia virus of mice (PVM) model. PVM is a host specific murine pneumovirus closely related to human RSV, which reproduces many of the features of RSV infection, such as high viral replication and neutrophil recruitment. Clinical disease and markers of lung inflammation and injury were studied in PVM-infected mice treated with either depleting or isotype control antibodies. To confirm our results we performed all experiments in two mice strains: C57Bl6 and BALBc mice. Neutrophil depletion in blood and lungs was efficient throughout the disease. Remarkably, in both mouse strains we found no difference in clinical disease severity between neutrophil-depleted and control arms. In line with this observation, we found no differences between groups in histopathological lung injury and lung viral loads. In conclusion, our study shows that in mice neutrophil recruitment to the lungs does not affect disease outcome or viral clearance during severe PVM infection. As such, this model does not support the notion that neutrophils play a key role in mouse pneumovirus disease.


Subject(s)
Disease Models, Animal , Murine pneumonia virus/immunology , Neutrophils/immunology , Pneumonia/immunology , Pneumovirus Infections/immunology , Respiratory Syncytial Virus Infections/immunology , Animals , Female , Humans , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Neutrophils/pathology , Pneumonia/pathology , Pneumovirus Infections/pathology , Respiratory Syncytial Viruses/immunology
16.
Sci Rep ; 6: 38139, 2016 12 01.
Article in English | MEDLINE | ID: mdl-27905537

ABSTRACT

Pneumonia Virus of Mice (PVM) is the only virus that shares the Pneumovirus genus of the Paramyxoviridae family with Respiratory Syncytial Virus (RSV). A deadly mouse pathogen, PVM has the potential to serve as a robust animal model of RSV infection, since human RSV does not fully replicate the human pathology in mice. Like RSV, PVM also encodes two nonstructural proteins that have been implicated to suppress the IFN pathway, but surprisingly, they exhibit no sequence similarity with their RSV equivalents. The molecular mechanism of PVM NS function, therefore, remains unknown. Here, we show that recombinant PVM NS proteins degrade the mouse counterparts of the IFN pathway components. Proteasomal degradation appears to be mediated by ubiquitination promoted by PVM NS proteins. Interestingly, NS proteins of PVM lowered the levels of several ISG (IFN-stimulated gene) proteins as well. These results provide a molecular foundation for the mechanisms by which PVM efficiently subverts the IFN response of the murine cell. They also reveal that in spite of their high sequence dissimilarity, the two pneumoviral NS proteins are functionally and mechanistically similar.


Subject(s)
Interferons/metabolism , Murine pneumonia virus/metabolism , Viral Nonstructural Proteins/metabolism , Animals , Cells, Cultured , Disease Models, Animal , Host-Pathogen Interactions/genetics , Host-Pathogen Interactions/immunology , Humans , Interferons/genetics , Metabolic Networks and Pathways/immunology , Mice , Murine pneumonia virus/genetics , Murine pneumonia virus/pathogenicity , Pneumovirus Infections/genetics , Pneumovirus Infections/immunology , Pneumovirus Infections/virology , Proteolysis , Respiratory Syncytial Virus Infections/etiology , Respiratory Syncytial Viruses/genetics , Respiratory Syncytial Viruses/metabolism , Respiratory Syncytial Viruses/pathogenicity , Viral Nonstructural Proteins/genetics
17.
Antiviral Res ; 135: 108-119, 2016 11.
Article in English | MEDLINE | ID: mdl-27771388

ABSTRACT

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections in infants and young children. There are no licensed RSV vaccines available, and the few treatment options for high-risk individuals are either extremely costly or cause severe side effects and toxicity. Immunomodulation mediated by a novel formulation consisting of the toll-like receptor 3 agonist poly(I:C), an innate defense regulator peptide and a polyphosphazene (P-I-P) was evaluated in the context of lethal infection with pneumonia virus of mice (PVM). Intranasal delivery of a single dose of P-I-P protected adult mice against PVM when given 24 h prior to challenge. These animals experienced minimal weight loss, no clinical disease, 100% survival, and reduced lung pathology. Similar clinical outcomes were observed in mice treated up to 3 days prior to infection. P-I-P pre-treatment induced early mRNA and protein expression of key chemokine and cytokine genes, reduced the recruitment of neutrophils and eosinophils, decreased virus titers in the lungs, and modulated the delayed exacerbated nature of PVM disease without any short-term side effects. On day 14 post-infection, P-I-P-treated mice were confirmed to be PVM-free. These results demonstrate the capacity of this formulation to prevent PVM and possibly other viral respiratory infections.


Subject(s)
Immunity, Innate , Immunologic Factors/administration & dosage , Murine pneumonia virus/immunology , Organophosphorus Compounds/administration & dosage , Pneumovirus Infections/prevention & control , Poly I-C/administration & dosage , Polymers/administration & dosage , Adjuvants, Immunologic , Administration, Intranasal , Animals , Cytokines/immunology , Immunologic Factors/chemistry , Immunologic Factors/immunology , Lung/virology , Mice , Mice, Inbred BALB C , Organophosphorus Compounds/immunology , Pneumovirus Infections/immunology , Poly I-C/immunology , Toll-Like Receptor 3/agonists
18.
Virology ; 497: 1-10, 2016 10.
Article in English | MEDLINE | ID: mdl-27400340

ABSTRACT

Respiratory syncytial virus (RSV) is a major cause of bronchiolitis and pneumonia in infants and pneumonia virus of mice (PVM) causes similar disease. BALB/c mice are highly susceptible, while C57BL/6 mice are more resistant to PVM. IL-12 was significantly more up-regulated in response to PVM infection in BALB/c than in C57BL/6 mice. IL-12p40-deficient neonatal and adult BALB/c mice showed significantly less weight loss than wild-type mice after PVM challenge. The percentage of regulatory T cells, as well as IFN-ß and IL-18 expression, was higher in the lungs of both neonatal and adult IL-12p40-/- mice. Adult IL-12p40-/- mice also showed enhanced TGF-ß and IL-10 expression and reduced inflammatory responses. Furthermore, IL-12p40-/- mice showed decreased sensitization to inhaled cockroach antigen after PVM infection when compared to wild-type mice. In conclusion, these data suggest that a depressed regulatory capacity in BALB/c mice to PVM infection results in enhanced immunopathology and sensitization to allergen.


Subject(s)
Allergens/immunology , Interleukin-12 Subunit p40/deficiency , Murine pneumonia virus/immunology , Pneumonia, Viral/etiology , Pneumonia, Viral/pathology , Weight Loss , Animals , Animals, Newborn , Gene Expression , Host-Pathogen Interactions/genetics , Host-Pathogen Interactions/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/metabolism
19.
Antiviral Res ; 132: 131-40, 2016 08.
Article in English | MEDLINE | ID: mdl-27312104

ABSTRACT

Pattern recognition receptors (PRRs) engage microbial components in the lung, although their role in providing primary host defense against respiratory virus infection is not fully understood. We have previously shown that Gram-positive Lactobacillus plantarum (Lp) administered to the respiratory tract promotes full and sustained protection in response to an otherwise lethal mouse pneumovirus (PVM) infection, a robust example of heterologous immunity. While Lp engages PRRs TLR2 and NOD2 in ex vivo signaling assays, we found that Lp-mediated protection was unimpaired in single gene-deleted TLR2(-/-) and NOD2(-/-) mice. Here we demonstrate substantial loss of Lp-mediated protection in a double gene-deleted NOD2(-/-)TLR2(-/-) strain. Furthermore, we demonstrate protection against PVM infection by administration of the bi-functional NOD2-TLR2 agonist, CL-429. The bi-functional NOD2-TLR2 ligand CL-429 not only suppresses virus-induced inflammation, it is significantly more effective at preventing lethal infection than equivalent amounts of mono-molecular TLR2 and NOD2 agonists. Interestingly, and in contrast to biochemical NOD2 and/or TLR2 agonists, Lp remained capable of eliciting primary proinflammatory responses from NOD2(-/-)TLR2(-/-) mice in vivo and from alveolar macrophages challenged ex vivo. Taken together, we conclude that coordinate engagement of NOD2 and TLR2 constitutes a key step in the genesis of Lp-mediated protection from a lethal respiratory virus infection, and represents a critical target for modulation of virus-induced inflammatory pathology.


Subject(s)
Immunomodulation , Nod2 Signaling Adaptor Protein/metabolism , Pneumovirus Infections/immunology , Pneumovirus Infections/metabolism , Pneumovirus/immunology , Signal Transduction , Toll-Like Receptor 2/metabolism , Animals , Cytokines/metabolism , Inflammation Mediators/metabolism , Lactobacillus plantarum/immunology , Ligands , Lung/immunology , Lung/metabolism , Lung/pathology , Lung/virology , Macrophages, Alveolar/immunology , Macrophages, Alveolar/metabolism , Mice , Mice, Knockout , Murine pneumonia virus/immunology , Nod2 Signaling Adaptor Protein/genetics , Pneumovirus Infections/mortality , Pneumovirus Infections/virology , Receptors, Pattern Recognition/metabolism , Toll-Like Receptor 2/genetics , Viral Load
20.
J Allergy Clin Immunol ; 138(5): 1326-1337, 2016 11.
Article in English | MEDLINE | ID: mdl-27236500

ABSTRACT

BACKGROUND: Frequent viral lower respiratory infections in early life are an independent risk factor for asthma onset. This risk and the development of persistent asthma are significantly greater in children who later become sensitized. OBJECTIVE: We sought to elucidate the pathogenic processes that underlie the synergistic interplay between allergen exposures and viral infections. METHODS: Mice were inoculated with a murine-specific Pneumovirus species (pneumonia virus of mice [PVM]) and exposed to low-dose cockroach extract (CRE) in early and later life, and airway inflammation, remodeling, and hyperreactivity assessed. Mice were treated with anti-IL-33 or apyrase to neutralize or block IL-33 release. RESULTS: PVM infection or CRE exposure alone did not induce disease, whereas PVM/CRE coexposure acted synergistically to induce the hallmark features of asthma. CRE exposure during viral infection in early life induced a biphasic IL-33 response and impaired IFN-α and IFN-λ production, which in turn increased epithelial viral burden, airway smooth muscle growth, and type 2 inflammation. These features were ameliorated when CRE-induced IL-33 release was blocked or neutralized, whereas substitution of CRE with exogenous IL-33 recapitulated the phenotype observed in PVM/CRE-coexposed mice. Mechanistically, IL-33 downregulated viperin and interferon regulatory factor 7 gene expression and rapidly degraded IL-1 receptor-associated kinase 1 expression in plasmacytoid dendritic cells both in vivo and in vitro, leading to Toll-like receptor 7 hyporesponsiveness and impaired IFN-α production. CONCLUSION: We identified a hitherto unrecognized function of IL-33 as a potent suppressor of innate antiviral immunity and demonstrate that IL-33 contributes significantly to the synergistic interplay between respiratory virus and allergen exposures in the onset and progression of asthma.


Subject(s)
Allergens/immunology , Asthma/immunology , Cockroaches , Cytokines/immunology , Insect Proteins/immunology , Murine pneumonia virus , Pneumovirus Infections/immunology , Air Pollutants/immunology , Animals , Asthma/virology , Bronchoalveolar Lavage Fluid/immunology , Bronchoalveolar Lavage Fluid/virology , Dendritic Cells/immunology , Lung/virology , Mice, Inbred BALB C , Pneumovirus Infections/virology , Viral Load
SELECTION OF CITATIONS
SEARCH DETAIL
...